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Abstract
Toxoplasma gondii is an obligatory intracellular parasite whose life
cycle may include man as an intermediate host. More than 500 million
people are infected with this parasite worldwide. It has been previ-
ously reported that T. gondii contains a superantigen activity. The
purpose of the present study was to determine if the putative
superantigen activity of T. gondii would manifest towards human T
cells. Peripheral blood mononuclear cells (PBMC) from individuals
with no previous contact with the parasite were evaluated for prolif-
eration as well as specific Vß expansion after exposure to Toxoplasma
antigens. Likewise, PBMC from individuals with the congenital infec-
tion were evaluated for putative Vß family deletions in their T cell
repertoire. We also evaluated, over a period of one year, the PBMC
proliferation pattern in response to Toxoplasma antigens in patients
with recently acquired infection. Some degree of proliferation in
response to T. gondii was observed in the PBMC from individuals
never exposed to the parasite, accompanied by specific Vß expansion,
suggesting a superantigen effect. However, we found no specific
deletion of Vß (or Va) families in the blood of congenitally infected
individuals. Furthermore, PBMC from recently infected individuals
followed up over a period of one year did not present a reduction of the
Vß families that were originally expanded in response to the parasite
antigens. Taken together, our data suggest that T. gondii does not have
a strong superantigen activity on human T cells.
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Introduction
Toxoplasmosis is caused by the intracel-
lular protozoan, Toxoplasma gondii. Ac-
quired disease may result in lymphadenopa-
thy, low-grade fever, and sore throat. The
disease often progresses to a symptomless
state in immunocompetent individuals (1,2).
In the immunocompromised host, encephali-
tis caused by the parasite may be fatal (3-6).
Infection during pregnancy occurs in two of
1000 cases in the United States with up to a
50% transplacental infection rate, with a
higher rate in other parts of the world (2,7,8).
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Acquired disease was thought to be rare.
However, several studies indicate that ocu-
lar lesions may be caused by T. gondii infec-
tion after birth (9-11).
Superantigens are molecules from mi-
croorganisms that can activate large num-
bers of T cells. These molecules stimulate T
cells due to their ability to interact with the T
cell receptor (TCR) Vß framework regions
(12) and possibly with Va elements (13). As
a consequence of such promiscuous interac-
tions, 2 to 30% of all T cells from one
individual may be stimulated by some super-
antigens. The in vivo effects of such massive
T cell stimulation are often deleterious (i.e.,
toxic shock syndrome and food poisoning in
humans). Unlike conventional antigens,
which are bound to the antigen-binding
groove on MHC molecules, superantigens
interact with MHC molecules outside the
peptide-binding groove and do not require
processing. Kappler and colleagues (14,15)
were the first to report superantigen activity.
They described a strain-specific deletion of
T cells expressing a specific Vß in mice. The
deletion was related to the presence of cer-
tain alleles of the minor histocompatibility
loci. Minor histocompatibility locus prod-
ucts have been known for their ability to
stimulate specific Vß-bearing T cells (16-
18). The cloning of these loci revealed that
they were endogenous retroviruses of the
mouse mammary tumor virus family and
that various family members bind to differ-
ent Vß domains (12,19,20). Others have re-
ported that staphylococcal enterotoxins (21)
and products from Yersinia pseudotubercu-
losis (22), Streptococcus (23), and Myco-
plasma also displayed superantigen-like ac-
tivities (24). In addition, viruses such as
rabies (25), Epstein Barr virus, and cytome-
galovirus (26) express superantigens. Proto-
zoans (Plasmodium falciparum) were also
reported to contain components with super-
antigen properties (27).
Recently, T. gondii was also suggested to
contain a component with superantigen ac-
tivity (28,29). These authors showed that
naive CD8+ cells bearing the Vß5.1 were
stimulated in the presence of the whole para-
site. This finding is of particular importance
since it has also been suggested that superan-
tigens might be involved in triggering au-
toimmune diseases. There is an ongoing dis-
cussion in the ophthalmic literature regard-
ing a possible role for autoimmunity in pa-
tients with recurrent ocular lesions follow-
ing infection with T. gondii. Therefore, we
set out to establish whether in humans the
most common effects of a superantigen were
detected following exposure to T. gondii or
its antigens. We were able to demonstrate
that T cells from some non-exposed indi-
viduals did proliferate in response to anti-
gens of the parasite. Furthermore, there were
expanded specific Vß families. In addition,
when the peripheral blood mononuclear cells
(PBMC) from individuals with congenital
disease were analyzed some deletions were
observed in the T cell repertoire. These data
suggest that indeed T. gondii has a super-
antigen that does activate and delete human
T cells. On the other hand, when T cells from
seronegative individuals were stimulated in
vitro with T. gondii antigens, expansion was
not followed by deletion of specific Vß fami-
lies. Furthermore, the deletions of TCR Vß
families observed in patients with congenital
toxoplasmosis were shared among their kin-
dred, even those that were not infected by
the parasite. Since deletion of responding
cells is a hallmark of superantigen activity,
we suggest that, although there is some evi-
dence for a superantigen activity in T. gondii,
it is not likely that such activity affects hu-
man cells.
Material and Methods
Patients
Blood samples were collected from 36
individuals who had negative antibody (IgM
and IgG) titers for T. gondii (less than 1:4),
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48 seropositive individuals (IgG titers above
1:16), and 11 patients with congenital toxo-
plasmosis. Antibody titers were determined
with a test kit from Sigma Chemical Co. (St.
Louis, MO, USA). The patients studied were
19 and 56 years old and came from Erechim
or Sªo Paulo, Brazil. All gave informed con-
sent to participate in the study. The clinical
status (congenital ocular toxoplasmosis or
absence of ocular lesions) of the individuals
evaluated was determined as previously de-
scribed (9,11,30). Briefly, patients were con-
sidered to have congenital toxoplasmosis
when their mother had a positive IgM re-
sponse to Toxoplasma antigens that devel-
oped during pregnancy and when ocular le-
sions were visualized by fundoscopy on the
occasion of their first visit to the ophthal-
mologist. None of the individuals studied
were under treatment with any immunosup-
pressive or immunomodulatory drug. Women
using oral anticonceptives were not included
in this study since previous unpublished re-
sults from our group indicate that they may
alter the antigen-specific response patterns
of T cells. Other drugs being used by the
patients during the study were antibiotics (2
patients), aspirin (2 patients), acetaminophen
(3 patients) and antihistamine (5 patients).
Patients with acute toxoplasmosis were di-
agnosed by their clinical features (malaise,
lymphadenopathy and sore throat) and based
on positive IgM titers to Toxoplasma anti-
gens. All procedures were approved by the
Ethics Committee of the institutions where
the patients were being followed up (UNIFESP,
USP).
Proliferation assays
Proliferation assays were performed as
described previously (31). Briefly, PBMC
obtained by gradient centrifugation were di-
luted to 106 cells/ml and added to 96-flat-
bottom well microtiter plates (Falcon). Cul-
tures were stimulated with 2.5 µg/ml of phy-
tohemagglutinin (PHA) or 5 µg/ml of soluble
toxoplasma tachyzoite antigen (STAg) or
control antigens (tuberculin purified protein
derivative (PPD) or tetanus toxoid), in a final
volume of 200 µl of RPMI 1640 per well
containing 5% AB+ human serum pooled
from blood donors. PBMC were cultured for
96 h and then pulsed with 0.5 µCi [H3]-
thymidine per well and processed accord-
ingly for standard gaseous or liquid
scintillography. Results are presented as stim-
ulation index units that represent the mean
proliferation in cpm in response to a given
stimulus divided by the mean background
proliferation of unstimulated cells. Stimula-
tion indices above two were considered posi-
tive. PBMC were obtained from blood drawn
at least one month after the last active epi-
sode of disease and before two months had
elapsed from that episode.
Soluble tachyzoite antigen preparation
STAg was prepared as described previ-
ously (32). Briefly, tachyzoites of the RH
strain were maintained by in vitro passage in
human foreskin fibroblasts at 37oC. For anti-
gen preparation, tachyzoites were harvested
from fibroblast cultures, passed through a
27-gauge needle, centrifuged at 70 g for 5
min and pelleted at 590 g for 10 min.
Tachyzoites were then sonicated 4 times for
20 s each round and centrifuged at 10,000 g
for 30 min. The supernatant preparation
termed STAg was used as antigen in the in
vitro assays.
Flow cytometry
Standard flow cytometry analysis was
performed using antibodies against human
Va and Vß chain from Endogen (Cambridge,
MA, USA) or from PharMingen (San Diego,
CA, USA). One million cells were stained
directly in a final volume of 100 µl PBS
according to manufacturer instructions and
read with a FACScan (Becton-Dickinson
Immunocytometry Systems, San Jose, CA,
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USA) using the Lysis II program or a
FACScallibur instrument (Becton-Dickin-
son) using the CellQuest program.
Reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis of the Vß TCR
chain
TCR analysis by RT-PCR was performed
as described previously (33). RNA from
PBMC was obtained using the RNAzol B
method, reverse transcribed and amplified
using primers described elsewhere (33). PCR
products were separated on 1.5% agarose
gels and analyzed by Southern blot hybrid-
ization with fluorescein-labeled internal
probes using the ECL-3 oligolabeling and
detection system and Hyperfilm-ECL (Amer-
sham Pharmacia Biotech, Little Chalfont,
UK).
Reagents
Isolymph was purchased from Gallard-
Schlesinger (Cale Place, NY, USA). PHA-p
was obtained from Difco Laboratories (De-
troit, MI, USA). Interleukin (IL)-2 was pur-
chased from Boehringer-Mannheim Corp.
(Mannheim, Germany), and human IL-4 and
IFN-a were purchased from Genzyme Diag-
nostics (Cambridge, MA, USA). Human
IL-1, IL-12 and TNF-a were obtained from
R&D Systems (Minneapolis, MN, USA),
and human IL-10 and IL-5 were from
PharMingen.
Statistical analysis
Data were analyzed by ANOVA Fisher
PLSD and by the Kruskal-Wallis test for
nonparametric data. Results were consid-
ered statistically different when a 95% con-
fidence level was achieved.
Results
In a recent population-based household
survey performed in Erechim, Southern Bra-
zil, 184 (17.7%) of 1042 individuals exam-
ined were considered to have ocular toxo-
plasmosis (9,11). Because of the high fre-
quency of the disease, its occurrence in mul-
tiple siblings, and its low prevalence in chil-
dren as compared to the adult population,
many of the ocular toxoplasmosis cases in
Erechim are thought to be sequelae of post-
natal infection (10).
Here we studied the immune response
against Toxoplasma antigens from patients
that have been followed by some of us
(Silveira C and Belfort Jr R, unpublished
data). Patients were divided into three groups:
a) normal controls with negative serology
for T. gondii, matched to the other groups for
sex and age, b) patients with positive serol-
ogy for T. gondii but without ocular lesions,
and c) patients with congenital toxoplasmo-
sis. In addition, we studied six patients who
had recently acquired toxoplasmosis and fol-
lowed their lymphocyte proliferative re-
sponse to T. gondii antigens and the pattern
of Va and Vß expression of their lympho-
cytes following stimulation with STAg.
Figure 1 shows the stimulation indices
(SI) obtained when PBMC from seronega-
tive and seropositive individuals were cul-
tured in the presence of STAg. Although
Figure 1. PBMC proliferation in re-
sponse to STAg. The box plot pre-
sents the proliferation of PBMC
from 36 seronegative individuals
and 48 individuals with previous
contact with Toxoplasma gondii
(seropositive). The data are ex-
pressed as stimulation index (SI).
The seronegative individuals had
a median (± SD) proliferation of
1.1 ± 2.4. The median SI for the
seropositive group was 11.5 ±
28.7. The mean SI of STAg for the
two groups was 2.3 and 20.9, re-
spectively. The average SI of PHA
in the groups was 29.8 and 30.1,
respectively (proliferation was measured at 48 h and antigen-specific proliferation at 96 h).
The average SI of PPD in the groups was 10.6 and 12.1, respectively. The average SI of
tetanus toxoid in the groups was 9.9 and 10.0, respectively. PBMC, peripheral blood
mononuclear cells; STAg, soluble toxoplasma tachyzoite antigen; PHA, phytohemaggluti-
nin; PPD, tuberculin purified protein derivative.
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some seronegative individuals had positive
proliferative responses (= 2 SI), most of
them did not respond to Toxoplasma anti-
gens. In contrast, PBMC from seropositive
individuals proliferated significantly in re-
sponse to STAg irrespective of the presence
of ocular lesions. There was no difference
between groups in response to PHA or unre-
lated antigens (PPD and tetanus toxoid).
Because PBMC from some individuals
in the seronegative group showed an in vitro
response to T. gondii antigens, it was sug-
gested that a superantigen activity was at
play. Therefore, we decided to analyze PBMC
from patients with congenital toxoplasmosis
for deletions of specific Vß-bearing lympho-
cytes. Those individuals were more likely to
carry deletions since they had been exposed
to the parasite antigens for the longest period
of time. The presence of Vß families was
tested by flow cytometry when antibodies
were available or by RT-PCR for the Vß
families against which antibodies were not
available. Deletions of Vß3, Vß12, Vß14
and Vß15 were observed (Figure 2). One
patient had a deletion of Vß5.1 cells, less
than 0.5% by flow cytometry (data not
shown). However, most patients did not show
any gaps in their Vß repertoire. The Vß
deletions found in patients with congenital
toxoplasmosis were often shared by nonin-
fected members of the same family, suggest-
ing that these were familial variations not
due to the nature of Toxoplasma infection.
However, it is still possible that deletion of
STAg-specific T cells does occur and the
methods used to evaluate TCR Va and Vß
families are not sensitive to detect minor
changes in these families.
Studies on mice have suggested that T.
gondii contains a superantigen-like activity
capable of selective induction of T cells
bearing the Vß5 chain both in vitro and in
vivo (28,29). Because superantigen stimula-
tion causes expansion, followed by deletion
of the T cells bearing the TCR with which
they interact, we hypothesized that if T. gondii
expresses a superantigen, exposure to STAg
would result in the expansion of T cells
bearing specific Vß in seronegative indi-
viduals. Therefore, we stimulated PBMC
from seronegative individuals with STAg.
Five days after stimulation, the Va and Vß
repertoire in culture was evaluated by flow
cytometry in comparison to the Va and Vß
repertoire expressed by unstimulated cells.
A Va or Vß was considered expanded if the
percentage of positive cells after stimulation
was at least two times higher than its fre-
quency in the unstimulated population. Nine
out of 26 seronegative individuals showed
an expansion of some T cells bearing the
Vß5.1 receptor (Table 1). Increases in the
percentage of T cells expressing Vß5.2/
Vß5.3, Vß6.7, Vß7.1, Vß8, Vß9 and Vß23
were also found. One patient showed a sig-
nificant expansion of Va12.1-bearing cells.
The fact that T cells from unexposed indi-
viduals proliferate in response to STAg does
support the hypothesis that a superantigen
expressed by T. gondii is capable of stimu-
lating human T cells. This hypothesis is fur-
ther supported by the finding that such pro-
liferation occurs through the expansion of
specific Vß-bearing T cells. Interestingly,
one of the Vß families that is found to be
expanded in patients after stimulation with
Vß2
Vß3
Vß4
Vß12
Vß13
Vß14
Vß15
HPRT
Patient
1 2 3 4 5 6 7 8 9 10 11
Figure 2. Peripheral blood mono-
nuclear cell expression of Vß
families as measured by RT-
PCR. Patients with congenital
ocular toxoplasmosis (1 to 11)
were evaluated for the presence
of the Vß families shown. Hypo-
xanthine phosphoribosyltrans-
ferase (HPRT) was used as a
housekeeping gene control.
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STAg is the same that is found to be ex-
panded in response to Toxoplasma stimula-
tion in the mouse (32). However, we found
no evidence of specific Vß family expansion
in ex vivo PBMC from individuals with con-
genital ocular toxoplasmosis, acquired ocu-
lar toxoplasmosis, or asymptomatic sero-
positive individuals (data not shown).
Because we found a degree of Vß-specif-
ic T cell expansion in response to STAg in
naive donors, we decided to investigate the
evolution of the T cell response to Toxo-
plasma antigens in individuals recently in-
fected with T. gondii. We studied six indi-
viduals who presented positive IgM titers to
T. gondii with classic symptoms of acute
infection (see Material and Methods). The
first three patients have been followed up for
over a year, three additional patients have
been followed up for different periods of
less than 240 days. Figure 3 shows that
proliferation in response to STAg does not
seem to decrease over the period of time the
patients were evaluated. Furthermore, flow
cytometry analysis of the Va and Vß ex-
panded upon STAg stimulation of the PBMC
from these patients showed that no families
were deleted over the study period (Table 2).
Table 1. Vß expression in peripheral blood mononuclear cells from seronegative
individuals after stimulation with soluble toxoplasma tachyzoite antigen (STAg).
Patient # Vß enhanced
1 Vß5.1 (50%)
2 Vß5.2/Vß5.3 and Vß9 (150 and 148%, respectively)
3 none
4 none
5 Vß5.1 (200%)
6 none
7 Vß5.1 and Vß8 (210 and 167%, respectively)
8 none
9 Vß5.1 and Vß7 (202 and 135%, respectively)
10 Vß5.1 and Vß6.7 (154 and 195%, respectively)
11 Va12.1 (149%)
12 none
13 Vß5.1 and Vß5.2/Vß5.3 (102, 183 and 190%, respectively)
14 Vß9 (163%)
15 Vß23 (102%)
16 none
17 Vß7.1 (111%)
18 none
19 Vß6.7 and Vß9 (123 and 200%, respectively)
20 Vß5.1 (157%)
21 Vß5.1 (132%)
22 Vß5.1 and Vß6.7 (173 and 229%, respectively)
23 none
24 Vß5.1 and Vß7.1 (139 and 213%, respectively)
25 Vß5.1 and Vß9 (166 and 191%, respectively)
26 none
Va or Vß was considered to be enhanced if the number of positive cells after exposure
to STAg was at least double the number of cells bearing the same Va or Vß in cultures
without stimulation. Percent increase in expression of Va or Vß over expression in
unstimulated cells is shown in parentheses.
Figure 3. PBMC proliferation
from six patients in response to
PHA (filled line and open sym-
bols), STAg (dotted line and
closed symbols) and PPD (thick
filled line and open symbols).
Each symbol  represents the pro-
liferation over time of one given
patient. The standard error is
shown for each point. PHA-stim-
ulated proliferation was meas-
ured at 48 h and antigen-specific
proliferation at 96 h. Proliferation
data are presented as stimula-
tion index (mean cpm with the
stimulus divided by the cpm ob-
tained in culture without the
stimulus). For abbreviations, see
legend to Figure 1.
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Taken together, these data do not support the
hypothesis that T. gondii bears a superanti-
gen that acts on human lymphocytes.
Discussion
The possibility that T. gondii carries a
superantigen has been extensively discussed
in the literature (28,29,34). Aside from its
scientific significance, this information also
carries important clinical implications. If con-
firmed, these findings could shed light on a
number of clinical idiosyncrasies observed
in some patients with Toxoplasma choriore-
tinitis, such as the number of recurrences
and the inconstant response to corticoste-
roids. It may also help to explain why pa-
tients with the congenital form of the disease
have a decreased immune response to the
parasites antigens.
We have shown that PBMC from more
than one third of the individuals with no
previous contact with T. gondii proliferated
in the presence of Toxoplasma antigens.
These data would confirm that the parasite
contains a superantigen capable of stimulat-
ing human T cells. However, when the same
cells were analyzed for Vß-specific dele-
tions we were unable to detect any deletion
of Vß families. Since superantigen stimula-
tion always results in the deletion of the
proliferating T cells, these conflicting re-
sults suggest that proliferation induced by
STAg in these naive individuals may be
due to some other cause rather than superan-
tigenic stimulation. To further evaluate the
question of specific Vß family deletions af-
ter stimulation with STAg, we studied the T
cell repertoire of individuals with congenital
toxoplasmosis. These studies revealed that
11 of 36 of these individuals presented spe-
cific Vß deletions (gaps) in their T cell reper-
toire. However, their siblings as well as other
members of the family also showed the same
deletions irrespective of their status regard-
ing the infection or contact with T. gondii.
These results suggest that the inability to
respond to Toxoplasma antigens by patients
with congenital toxoplasmosis cannot be
explained on the basis of T cell repertoire
gaps caused by superantigenic stimulation
over a prolonged period of time (35). Fi-
Table 2. Flow cytometry analysis of the Va and Vß expression by peripheral blood mononuclear cells from patients with acute toxoplasmosis after
stimulation with soluble toxoplasma tachyzoite antigen (STAg).
Patient Va or Vß expanded (15 days) Va or Vß expanded (60 days) Va or Vß expanded (120 days) Va or Vß expanded (360 days)
1 Vß9 (103%), Vß8 (101%), Vß9 (98%), Vß8 (105%), Vß9 (100%), Vß8 (75%), Vß9 (98%), Vß8 (105%),
 Vß5.1 (87%)  Vß5.1 (97%), Va2 (55%)  Vß5.1 (105%), Va2 (55%) Vß5.1 (97%), Va2 (55%)
2 Vß6.7 (107%), Vß9 (75%) Vß6.7 (101%), Vß9 (85%), Vß6.7 (107%), Vß9 (75%), Vß6.7 (97%),
Vß8 (63%) Vß8 (43%), Va2 (45%) Vß9 (55%), Vß8 (73%)
3 Vß7.1 (112%) Vß7.1 (103%), Vß7.1 (105%), Vß7.1 (98%),
Vß5.2/Vß5.3 (95%) Vß5.2/Vß5.3 (101%) Vß5.2/Vß5.3 (109%)
4 Vß8 (120%), Vß5.1 (95%) Vß8 (120%), Vß5.1 (95%) Vß8 (150%), Vß5.1 (105%), NT
Vß13 (57%)
5 Vß3.1 (101%), Vß23 (75%) Vß3.1 (101%), Vß23 (75%) Vß3.1 (101%), Vß23 (75%), NT
Vß3 (62%), Vß2 (43%)
6 Vß13 (100%), Vß7.1 (65%) Vß13 (98%), Vß7.1(85%) Vß13 (111%), Vß7.1 (33%) NT
Va or Vß was considered to be enhanced if the number of positive cells after exposure to STAg was at least double the number of cells bearing the
same Va or Vß in cultures without stimulation. Percent increase in expression of Va or Vß over expression in unstimulated cells is shown in
parentheses. NT: not tested; these patients were followed up for a shorter period of time.
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nally, when we analyzed the evolution of the
T cell immune response to STAg in patients
recently infected with T. gondii, we were
unable to show any changes in the Vß fami-
lies they express. It is possible that the meth-
ods used to analyze T cell deletion (flow
cytometry and PCR) were not sensitive enough
to detect minor changes in the T cell reper-
toire. Nevertheless, the literature indicates that
changes induced by a superantigen are usu-
ally easily detected by such methods (36,37).
Taken together, our data strongly suggest
that T. gondii does not contain a superantigen
capable of stimulating human lymphocytes.
However, if a superantigen is not respon-
sible for the stimulation induced by STAg in
naive cells, why do they proliferate? A dis-
tinct possibility is the cross-reactivity be-
tween Toxoplasma antigens and a previously
encountered antigen. T cells that react to
Toxoplasma have been reported to recog-
nize other parasites (35,38,39). It remains to
be investigated which antigen or antigens
might be involved in the individuals evalu-
ated in this study. The seronegative volun-
teers had an unremarkable clinical history,
without any uncommon infectious episodes,
suggesting that the antigen(s) is(are) of a
common nature, either from another micro-
organism or from environmental sources such
as food. It is of interest that, whatever the
cross-reactive antigen might be, it does not
stimulate a humoral response. This would
not be a first since a similar situation has
been reported for Chagas disease (40). In
Chagas disease, lymphocytes from normal
individuals used as controls responded with
proliferation and cytokine production fol-
lowing stimulation with the Trypanosoma
cruzi antigen protein B13.
We suggest that T. gondii does not have a
superantigen that stimulates human T cells.
We also suggest that cross-reactivity is re-
sponsible for the lymphocyte proliferation
observed in response to T. gondii in sero-
negative patients.
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